Jennifer Clark
Primary Care · Dallas, TXNPI 1649993320
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 199 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 14.5% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 199 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$525
- Amgen$499
- AstraZeneca$484
- Lilly USA, LLC$310
- Pfizer$204
- Boehringer Ingelheim$162
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,609100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 30 | $525 |
| Amgen | 34 | $499 |
| AstraZeneca | 25 | $484 |
| Lilly USA, LLC | 17 | $310 |
| Pfizer | 9 | $204 |
| Boehringer Ingelheim | 8 | $162 |
| Otsuka America Pharmaceutical, Inc. | 6 | $153 |
| Bayer | 10 | $146 |
| Novartis | 6 | $104 |
| Exact Sciences | 6 | $102 |
| E.r. Squibb & Sons, L.L.C. | 5 | $100 |
| Sumitomo Pharma America, Inc. | 5 | $99 |
| Esperion Therapeutics, Inc. | 5 | $93 |
| Novo Nordisk | 5 | $85 |
| Eisai Inc. | 3 | $76 |
| Amarin Pharma, Inc. | 3 | $62 |
| Johnson & Johnson | 3 | $57 |
| Axsome Therapeutics, Inc. | 2 | $49 |
| Dexcom, Inc. | 2 | $38 |
| Antares Pharma, Inc. | 2 | $38 |
| Astellas Pharma US Inc | 2 | $31 |
| Philips North America LLC | 2 | $28 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Teleflex LLC | 1 | $28 |
| GSK | 1 | $27 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Shield Therapeutics Inc | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$120
How this compares
$3,609 in reported general payments places this provider in the 90th percentile of 563 primary care providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 64 | $69,311 |
| OzempicSemaglutide | 51 | $54,511 |
| TrulicityDulaglutide | 16 | $32,993 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 42 | $30,764 |
| JardianceEmpagliflozin | 17 | $28,507 |
| XareltoRivaroxaban | 22 | $26,766 |
| MounjaroTirzepatide | 22 | $22,264 |
| KerendiaFinerenone | 12 | $17,883 |
| EntrestoSacubitril/Valsartan | 18 | $13,553 |
| Rosuvastatin Calcium | 409 | $4,311 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $3,644 |
| Icosapent Ethyl | 11 | $3,214 |
| Ezetimibe | 126 | $2,296 |
| Azelastine Hcl | 23 | $1,164 |
| Esomeprazole Magnesium | 18 | $1,127 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $484 | $69,31164 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance | $162 | $59,27159 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $310 | $55,25738 claims |
| Novo NordiskOzempic | $85 | $54,51151 claims |
| Johnson & JohnsonXarelto | $57 | $26,76622 claims |
| BayerKerendia | $146 | $17,88312 claims |
| NovartisEntresto | $104 | $13,55318 claims |
| AbbVieSynthroid | $525 | $39016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 563 primary care providers in Texas.
Other primary care in Dallas
- Herbert BautistaDallas$14K
- Lindsey RigsbyDallas$4K
- Carmen SaloneDallas$4K
- Mary GibbensHouston$42K
- Phillip GulleySan Antonio$23K
- Brandi JoynerLongview$12K
- Steven ParisAustin$10K
- Hope OdomCollege Station$10K
- Arlena GraysTomball$9K
- Charlotte BallardSan Antonio$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.